British Journal of Haematology, 0007-1048

Journal

1 - 10 out of 142Page size: 10

Publications

  1. 2020
  2. Published

    Adjuvant tyrosine kinase inhibitor therapy improves outcome for children and adolescents with acute lymphoblastic leukaemia who have an ABL‐class fusion

    & 8 others, , 14 Dec 2020, In: British Journal of Haematology.

    Research output: Contribution to journal › Article › peer-review

  3. E-pub ahead of print

    COVID-19 in haematology patients: a multicentre West Midlands clinical outcomes analysis on behalf of West Midlands Research Consortium

    Anandadeep Mandal, Dickens Pratt, 5 Nov 2020, (E-pub ahead of print) In: British Journal of Haematology.

    Research output: Contribution to journal › Letter › peer-review

  4. Published

    COVID-19 in haematology patients: A multi-centre West Midlands clinical outcomes analysis on behalf of West Midlands Research Consortium: Impact of COVID-19 on Haematology Patients

    Anandadeep Mandal, 5 Nov 2020, In: British Journal of Haematology.

    Research output: Contribution to journal › Article › peer-review

  5. Published

    Acute myeloid leukaemia therapeutic innovation and clinical trials: past, present and future

    Charles Craddock, Nov 2020, In: British Journal of Haematology. 191, 4, p. 568-572 5 p.

    Research output: Contribution to journal › Article › peer-review

  6. E-pub ahead of print

    How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML).

    Sylvie Freeman, Oct 2020, (E-pub ahead of print) In: British Journal of Haematology.

    Research output: Contribution to journal › Article › peer-review

  7. E-pub ahead of print

    Adjuvant tyrosine kinase inhibitor therapy improves outcome for children and adolescents with acute lymphoblastic leukaemia who have an ABL-class fusion

    & 8 others, , 14 Sep 2020, (E-pub ahead of print) In: British Journal of Haematology.

    Research output: Contribution to journal › Article › peer-review

  8. E-pub ahead of print

    Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response-adapted design in the first-line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY)

    Sarah Pirrie, Eszter Nagy, Keith Wheatley, 14 Sep 2020, (E-pub ahead of print) In: British Journal of Haematology.

    Research output: Contribution to journal › Article › peer-review

  9. E-pub ahead of print

    Diagnostic pathways in multiple myeloma and their relationship to end organ damage: an analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) trial

    Catherine Atkin, Dickens Pratt, Mark Drayson, 15 Aug 2020, (E-pub ahead of print) In: British Journal of Haematology.

    Research output: Contribution to journal › Article › peer-review

  10. E-pub ahead of print

    Medical therapy to attenuate fetal anaemia in severe maternal red cell alloimmunisation

    Mark Kilby, 14 Aug 2020, (E-pub ahead of print) In: British Journal of Haematology.

    Research output: Contribution to journal › Article › peer-review

  11. Published

    The prevalence and significance of monoclonal gammopathy of undetermined significance in acute medical admissions

    Catherine Atkin, Mark Drayson, Elizabeth Sapey & Alex Richter, 1 Jun 2020, In: British Journal of Haematology. 189, 6, p. 1127-1135 9 p.

    Research output: Contribution to journal › Article › peer-review

Previous 1 2 3 4 5 6 7 8 ...15 Next